Mira Pharmaceuticals (MIRA) Short term Debt (2022 - 2023)
Mira Pharmaceuticals (MIRA) posted Short term Debt of $1.8 million for Q2 2023, up 1254.99% sequentially from $133062.0 in Q4 2022.
Mira Pharmaceuticals (MIRA) Short term Debt (2022 - 2023) Analysis & Trends
Mira Pharmaceuticals has reported Short term Debt for 2 years, with the latest figure at $1.8 million in Q2 2023.
- Quarterly Short term Debt changed N/A year-over-year to $1.8 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $1.8 million (changed N/A YoY) and the FY2022 annual result came in at $133062.0, changed N/A from the prior year.
- Short term Debt climbed to $1.8 million in Q2 2023 per MIRA's latest filing, from $133062.0 in the prior quarter.
- Over five years, Short term Debt peaked at $1.8 million in Q2 2023 and troughed at $133062.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.80 Mn |
| Dec 31, 2022 | 133,062.00 |